Google Custom Search
Podcast Advocacy 2014 HBV Meeting navigation menu


PA Biotech
Liver Cancer Connect
Visit our Baruch Blumberg Institute of Living Science
World Hepatitis Alliance Member
HepB United

Top Stories    

*Please Note: Links to full articles may expire after 2 weeks. If you are unable to access the page via the links below, try searching the HBV Research List Archives at


Biochemist's Find is New Hope for Hep B Cure
July 21 – Dr. Adam Zlotnick at Indiana University has discovered a class of antiviral small molecules that target the viral DNA hidden in the infected livers of hepatitis B patients and could lead to a cure. Novel compounds based on these discoveries, known as Core Protein Allosteric Modulators, or CpAMs, are capable of altering the activities of a core hepatitis B protein that is essential for the virus’s continued survival. Read more.

New York City's Top Hospitals Fail to Vaccinate Newborns Against Hep B, Study Shows
July 21 – All babies should receive the hepatitis B vaccination as soon as they’re born, federal officials say, but advocates say some of the city’s top hospitals are not following recommendations, putting the babies at risk for infection. Two of the hospitals with the lowest vaccination rates in the city are Mount Sinai and Beth Israel, where fewer than 20 percent of babies received the HBV vaccine in 2012, according to Health Department data. And at Maimonides, Tisch and Roosevelt hospitals, just 20 to 40% of newborns got the vaccine that same year. Read more.

HBV Rebounds After Stopping Entecavir, Switching to Interferon May Help
July 21 – Most hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B patients relapsed after stopping treatment with the antiviral drug entecavir (Baraclude), according to a report Gut. A related study found that switching from entecavir to pegylated interferon increased the likelihood of HBeAg seroconversion and hepatitis B surface antigen (HBsAg) loss in HBeAg positive patients. Read more.

Screening for Hepatitis B Virus Infection: A Public Health Imperative
July 7 – Annals of Internal Medicine editorial provides a clear rationale for the updated USPSTF recommendations, and reflects the HBF’s position on screening for hepatitis B. Read more.

Tenofovir Usually Suppresses Hepatitis B in HIV/HBV Coinfected People
July 7 – Tenofovir led to undetectable hepatitis B virus levels in 87% of HIV positive coinfected individuals, and a similar proportion maintained viral suppression over 6 years, according to a study described in Hepatology. Read more.

Super-Cooled Livers Could Bring New Flexibility to Organ Transplants
July 7 – In liver transplantation, one of the biggest inequities is geographic. A group of Harvard University researchers has come up with a preservation technique that could one day allow livers to be shared more easily around the world. Read more .

Drug Everolimus Fails to Improve Overall Survival in Advanced Liver Cancer Patients
July 7 – Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. Read more.

No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment
June 30 – No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in Clinical Gastroenterology and Hepatology. Read more.

GAVI Alliance Addresses MSF Concerns on Infant Hepatitis B Vaccine
June 30 – Medecins Sans Frontieres recently expressed concern about the slow implementation of the World Health Organization’s recommendation that a dose of hepatitis B vaccine be delivered immediately after birth, and the GAVI alliance has resplied. Read more.

Fighting Hepatitis B and Liver Cancer in West Africa
June 30 – EU-funded researchers are identifying and treating patients with Hepatitis B in West Africa with the aim of reducing their risk of dying from liver cancer. The researchers are also developing a new test to identify those with liver cancer, so treatment can be given sooner – saving more lives. Read more.

Okyeame Kwame Fights Against Hepatitis B
June 30 – As part of activities to mark this year’s World Hepatitis B Day, Ghana’s award-winning hiplife artiste, Okyeame Kwame, will organize a free Hepatitis B screening event for 5000 people in Accra. Read more.

Screening Can Identify Early-Stage HCC But Benefits Unclear
June 23 – Chronic hepatic disease has been recognized as a risk factor for hepatocellular carcinoma, but does that mean that all patients should be screened? See what a recent study published in the Annals of Internal Medicine has to say. Read more.

WHO Calls for National Actions on Hepatitis
June 23 – Though home to about one quarter of the world population, the WHO Region for the Western Pacific accounts for nearly 50% of the 160 million chronic hepatitis B infections worldwide. Read more.

HIV infection Due to Unsafe Medical Injections May Have Fallen by Almost 90% Worldwide in Decade After 2000
June 23 – The number of HIV, hepatitis B and C infections in low and middle-income acquired due to unsafe medical injections fell by 87%, 83%, and 91% respectively between 2000 and 2010. "This is a remarkable public health achievement.” Read more.

Mayo Clinic Study Reverses Current Thought on Treatment of Cirrhosis
June 23 – Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. Read more.

Something to Celebrate: Improved Guidelines for Hepatitis B Screening
June 2 – The month of May gave us many reasons to celebrate. Reflecting on Asian American and Pacific Islander (AAPI) Heritage and Hepatitis Awareness Month, appreciating the rich AAPI history, and recognizing the importance of addressing viral hepatitis in AAPI populations. Read more.

Combating the Silent Epidemic of Hepatitis B in the AAPI Community
June 2 – Dr. Howard Koh, Assistant Secretary of Health, HHS, reminds us of the staggering impact of Hepatitis B in Asian American and Pacific Islanders, and how coordination and collaboration among federal partners works to reduce the burden of hepatitis B in these communities. Read more.

Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
June 2 – Among HBV/HCV coinfected people, about half have dominant hepatitis B virus while half have dominant hepatitis C, and those with active HBV replication are at higher risk of liver-related complications and death, according to study findings presented at Digestive Disease Week. Read more.

Hepatitis Warrior Hiking in China Shows Glaxo Hurdles
June 2 – Lei Chuang trekked almost 1,000 miles over 80 days from Shanghai to Beijing last summer, along riverbanks and highways, to deliver a petition beseeching China’s leaders to cut the prices of hepatitis B drugs. Read more.

Screening for Hepatitis B Virus Infection: A Public Health Imperative
May 26 – The U.S. Preventive Services Task Force, a national panel of health experts, advised that doctors should regularly screen people at high risk for contracting the hepatitis B virus. Read more.

World Health Assembly Approves Resolution on Viral Hepatitis and Noncommunicable Dieases
May 26 – The World Health Assembly has approved a resolution to improve the prevention, diagnosis, and treatment of viral hepatitis, as well as proposals to improve global coordination of efforts to address noncommunicable diseases. Read more.

Passing Hepatitis B From Mother to Child Halted With Vaccine
May 26 – The passing of the hepatitis B virus, a primary cause of liver cancer, from mother to child can be virtually eliminated by immunizing high-risk newborns within hours of birth and following up with vaccinations over the baby's first six months of life, according to a large, recently published, Northern California Kaiser study. Read more.

Talking About Hepatitis B and HIV: Working to End the Stigma
May 26 – Hepatitis B and HIV have stigmatizing effects within the Asian American and Pacific Islander communities. Read Mei’s personal account of how she copes. It’s time to diffuse the stigma. Read more.

Alnylam's Hepatitis B Therapy Shows Promise in Animal Studies
May 19 – RNAi specialist Alnylam is adding a hepatitis B therapy to its pipeline of candidates that employ its enhanced stabilization chemistry-GalNAc-conjugate technology enabling subcutaneous dosing. Read more.

Robust Hepatitis B Seroprotection in Adolescence After Immunization in Infancy
May 19 – The complete hepatitis B vaccine series given in childhood has been shown to provide protection against HBV into adulthood. However the duration of protection if administered in infancy was uncertain, raising the question, is a booster dose of the vaccine in adolescence necessary? Read more.

What Every Women Needs to Know about Hepatitis B and C
May 19 – In observance of National Women’s Health Week and Hepatitis Awareness Month, Health and Human Services (HHS) Viral Hepatitis Policy Advisor Corinna Dan, takes the opportunity to raise viral hepatitis awareness among women. Read more.

Treating Hepatitis B and C in HIV + People Reduces Liver Disease
May 19 – Effective antiviral treatment that suppresses hepatitis B virus replication or eradicates hepatitis C virus can lower the risk of developing advanced liver disease including cirrhosis, hepatocellular carcinoma, and decompensation in people with HIV and viral hepatitis coinfection, according to studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) and EASL. Read more.

Some Hepatitis B Patients Can Stop Antiviral Treatment Without Relapse
May 12 – Stopping antiviral therapy after several years appears generally safe for people with HBeAg negative chronic hepatitis B without liver cirrhosis, and a substantial proportion do not experience viral relapse or worsening liver inflammation while off treatment, according to a pair of posters presented at Digestive Disease Week. Read more.

HBV: Community-Based Programs May Improve Care
May 12 – Community outreach programs, helped along by funding from the Centers for Disease Control and Prevention, may be improving the screening, treatment, and care of patients with hepatitis B virus infection, according to an article published in the Morbidity and Mortality Weekly Report. Read more.

Novira Kicks Off Phase 1a Trial of Novel Hep B Drug
May 12 – Novira Therapeutics Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus infection, announced that it initiated a Phase 1a clinical study of NVR-1221. The Phase 1a clinical study is designed to assess the pharmacokinetic profile and dose-related safety and tolerability of NVR-1221 in healthy volunteers. Read more.

Screening May Help Boost Liver Cancer Survival Rates
May 12 – Increased screening for liver tumors in people with cirrhosis could help boost liver cancer survival rates, according to researchers, but unfortunately they found less than 20% of at-risk people are being tested. Read more.

May is Hepatitis Awareness Month
May 5 – Throughout May, during this year’s observance of Hepatitis Awareness Month, federal colleagues from across the U.S. Departments of Health and Human Services, Housing and Urban Development, Justice, and Veterans Affairs will be engaged in a variety of activities to increase awareness—among the public and healthcare providers—about viral hepatitis. Read more.

The B Positive Program as a model to reduce hepatitis B health disparities in high-risk communities in Australia
May 5 – The B Positive Program addresses the challenges in diagnosing and managing hepatitis B in culturally and linguistically diverse communities in high-risk communities in Australia. Read more.

Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission
May 5 – An investigational vaccine known as Sci-B-Vac given to babies born to women with hepatitis B was more effective at preventing HBV infection than the widely used Engerix-B vaccine, according to a report at the 2014 EASL International Liver Congress. Read more.

Acetaminophen in Rx drugs: For Liver's Sake, Lower the Dose, Says FDA
May 5 – A Food and Drug Administration (FDA) warning was missed by many physicians, pharmacists and patients, so the FDA, in an unusual move, reminds us: Stop writing prescriptions for, stop dispensing prescriptions for, and stop taking prescription medications containing more than 325 milligrams of acetaminophen. Read more.

Some Immigrants In Columbus At Risk For Silent Killer
April 28 – Central Ohio is home to some 70,000 Asian immigrants, and advocates worry the silent deadly disease, hepatitis B, is hidden in the population. Read more.

Hepatitis B is Not Hindrance For Work
April 28 – Employers should neither isolate nor discriminate against workers who are Hepatitis B positive, the Hepatology Society of the Philippines (HSP) strongly voiced. HSP has written the Guidelines on the Evaluation of Hepatitis B Surface Antigen Positive Workers for Employment to dispel misconceptions and lack of knowledge about HBV in the Philippines. Read more.

Herbal Medicines and Supplements Carry Risk of Hepatoxicity
April 28 – Herbal medicines and other home remedies or supplements are a significant cause of hepatotoxicity experts warned recently during a symposium at the International Liver Congress. Read more and watch the videos.

Fiji Babies Covered
April 28 – This year’s immunization week celebrations in Fiji are focused on promoting vaccination against hepatitis B with the theme ‘Stop hepatitis B and liver cancer – Vaccinate at Birth’. Read more.

Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
April 21 – Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49th EASL International Liver Congress last week in London. Read more.

Asia-Pacific Nations Prodded On Hepatitis Action Plans
April 21 – Health experts state that the Asia-Pacific region needs more cross-sector partnerships and funding to tackle viral hepatitis, and they are calling on countries in the Asia-Pacific to set national action plans to address the escalating impact of viral hepatitis. Read more.

Teen Makes Genetic Discovery of Her Own Rare Cancer
April 21 – Inspiring story of a teen with a rare from of liver cancer that not only recovered from her cancer, but embarked on a scientific journey using YouTube to reach out to other patients to collect tumor samples that would eventually lead to a cutting edge discovery. Read more and watch the videos.

Can Coffee Treat Liver Disease?
April 21 – Contemporary studies suggest that coffee is beneficial for chronic liver diseases and can positively impact liver function tests, viral hepatitis, and may even help prevent cirrhosis and liver cancer. Read more.

Three New Studies Help Clarify Optimal Use of Combination Therapy in Chronic Hepatitis B Patients
April 14 - Three new studies presented at the International Liver Congress 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues to achieve the best treatment outcomes in patients with chronic hepatitis B. Read more.

Viral Hepatitis More Deadly Than HIV in Europe
April 14 – Mortality from viral hepatitis is significantly higher than from HIV/AIDS across European Union (EU) countries, according to results from The Global Burden of Disease Study 2010, which was announced for the first time at the International Liver Congress 2014. Read more.

Small Cash Incentives Dramatically Improve Hepatitis B Vaccination Rates Among Injecting Drug Users
April 14 – Modest financial incentives significantly improve adherence to hepatitis B virus vaccination programs among patients receiving opioid dependence treatment, according to a study published in The Lancet. Read more.

New Marker to Predict Recurrence of Hepatocellular Carcinoma
April 14 – High preoperative levels of hepatitis B surface antigen (HBsAg) in patients with a low viral load predict an increased likelihood of hepatocellular carcinoma recurrence after resection, Chinese researchers report. Read more.

Updated Viral Hepatitis Action Plan Released
April 7 – An updated version of the nation’s first comprehensive cross-governmental action plan to combat chronic viral hepatitis, initially launched in 2011, has been released. The Action Plan for the Prevention, Care and Treatment of Viral hepatitis builds upon the progress accomplished over the past three years. Read more.

Screening for Liver Cancer in Patients With Cirrhosis
April 7 – Patients with cirrhosis who underwent surveillance via liver ultrasound for hepatocellular carcinoma had cancers detected at an earlier stage, and were more likely to receive curative instead of palliative treatment, and had longer survival. Read more.

High Hepatitis B Antigen Predicts Hepatic Cancer Recurrence
April 7 – The risk of hepatocellular carcinoma recurrence increased with high levels of hepatitis B surface antigen (HBsAg) , specifically at HBsAg above 1000 IU/mL. Read more.

Some of Us are Turning Our Livers Into 'Foie Gras'
April 7 – While most of us are more familiar with viral hepatitis, alcohol-related liver disease and liver cancer, there is another condition affecting the liver that is insidiously rising amongst the world population. Read more.

Hep B Cure Could Be Discovered in Bucks Co.
March 24 – When a hepatitis B cure is discovered, it might very well happen inside the walls of the Pennsylvania Biotechnology Center in Bucks County. Read more.

Entecavir Approved for Children 2 Years and Older for Hepatitis B virus Infection
March 24 – The U.S. Food and Drug Administration has approved the antiviral entecavir (brand name Baraclude) for use in children and teens age 2 and older. This robust antiviral is the first to be approved by the FDA for children in several years, and is considered one of the top two antivirals available to adults today. Read more.

Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients
March 24 – Arrowhead Research Corporation announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. The Company anticipates planned enrollment to be complete in the second quarter of 2014 and expects top line results to be released in the third quarter. Read more.

Isis Announces Antisense Targeting of HBV Produces Dose-Dependent Reductions in Hepatitis B Virus
March 24 – Isis Pharmaceuticals announced that treatment with an antisense compound targeting hepatitis B virus produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These data will be presented at the 49th annual meeting of the European Association for the Study of the Liver (EASL). Read more.

Responding to the Escalating Impact of Viral Hepatitis in Asia Pacific
March 17 – Professor Ding-Shinn Chen, Chair of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP), addresses newly released data which CEVHAP will use to continue to raise awareness of the escalating impact of viral hepatitis in the Asia Pacific region. Read more.

HCC Risk Remains High With Hep B Antivirals
March 17 – Chronic hepatitis B patients who achieve complete response with oral antiviral therapy are still at much higher risk of developing hepatocellular cancer compared to patients with inactive chronic hepatitis B, Korean researchers find. Read more.

Vertical Transmission of Hep B On the Way Out
March 17 – Tenofovir in pregnant women with hepatitis B is extremely effective in preventing in utero infection and in combination with vaccination could eradicate the disease altogether, a New Zealand expert says. Read more.

Roadside Barbers: Main Cause of Communicable Diseases
March 17 – The use of unsterilized equipment by roadside barbers is the main cause of spreading communicable diseases, including Hepatitis B and C, in the twin cities of Pakistan. Read more.

Hepatera Completes Enrollment of Phase IIa Clinical Trial of Myrcludex B, for HBV
March 10 – A group of 48 patients infected with the hepatitis B virus have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd., with the aim to study safety, tolerability and efficacy. Read more.

Metabolic Profiling of Liver Cells Suggests New Treatments for Cirrhosis Patients
March 10 – In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University–led team of researchers examined the metabolic breakdown that takes place in liver cells during late–stage cirrhosis and found clues that suggest new treatments to delay liver failure. Read more.

Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop Liver Cancer Drug
March 10 – Biostar Pharmaceuticals, Inc., a China–based manufacturer and marketer of pharmaceutical and health supplement products, announced that it has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on Oleanolic Acid injection. Read more.

Hepatera Completes Enrollment of Phase IIa Clinical Trial of Myrcludex B, for HBV
March 10 – A group of 48 patients infected with the hepatitis B virus have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd., with the aim to study safety, tolerability and efficacy. Read more.

Metabolic Profiling of Liver Cells Suggests New Treatments for Cirrhosis Patients
March 10 – In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University–led team of researchers examined the metabolic breakdown that takes place in liver cells during late–stage cirrhosis and found clues that suggest new treatments to delay liver failure. Read more.

Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop Liver Cancer Drug
March 10 – Biostar Pharmaceuticals, Inc., a China–based manufacturer and marketer of pharmaceutical and health supplement products, announced that it has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on Oleanolic Acid injection. Read more.

Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
March 3 – Arrowhead Research Corporation announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus infection. Read more.

Adult Immunization Retake: Lost Opportunities for Protection, Shared Responsibility
March 3 – According to Medscape, only 65% of healthcare professionals have been vaccinated to protect against hepatitis B in the U.S. Read more.

WHO Official Urges Hepatitis B Education in China
March 3 – While praising China’s efforts in reducing hepatitis B, Dr. Shin Young-soo, the World Health Organization (WHO) Western Pacific regional director, stressed more effort is needed to fight discrimination against hepatitis B virus carriers in China. Read more.

Small man, Great Power
March 3 – A chronic hepatitis B carrier in China shows the impact one, small man can have by empowering others with his sense of justice, and his courage to disclose his chronic HBV infection, and publicly raise awareness. Read more.

Degradation of Viral DNA in the Cell Nucleus Opens New Hepatitis B Treatment Possibilities
Feb 24 – New data reveals how the viral DNA of the hepatitis B virus can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated, without damage to the liver cell, report scientists from the Helmholtz Zentrum München and the Technische Universität München in the journal, Science. Read more.

Hepatitis B Virus-Related Hepatocellular Carcinoma is Induced by MicroRNA-181a
Feb 24 – Researchers at Chongqing Medical University in China broke new ground on an association between microRNAs and hepatocellular carcinoma, the second leading cause of cancer-related deaths worldwide. Read more.

How to Turn Skin Cells Into Functioning, Mature Liver Cells
Feb 24 – Researchers have discovered a way to transform skin cells into mature, fully functioning liver cells that flourish on their own, even after being transplanted into laboratory animals modified to mimic liver failure, raising the hopes for millions at risk for developing liver failure. Read more.

WHO: Liver Cancer Moves to the 2nd Leading Cause of Cancer Deaths in the World
Feb 17 – Based on the latest statistics from WHO on trends in cancer incidence and mortality worldwide, the cancer burden is growing, and liver cancer has moved from third to now the second leading cause of cancer death worldwide. Read more.

Are Doctors Screening Their Patients for Hepatitis B?
Feb 17 – Dr. Curtis T. Miyamoto, president of the Philadelphia County Medical Society, speaks with HBF’s own Chari Cohen and Daniel Chen about local efforts and encourages hepatitis B screening of at-risk patients. Read more.

Austrian Red Cross in Hot Water After ‘Rejecting’ Blood Donations From Muslims
Feb 17 – Austria's Red Cross has come under fire from the local Islamic community after one of its doctors reportedly refused to accept blood donations from Muslims or donors of Turkish origin due to the risk of Hepatitis B. Hopefully Nucleic-Acid Amplification testing (NAT) is standard for all Austrian blood donations. Read more.

Fighting Hepatitis B and Liver Cancer in West Africa
Feb 10 – European Union (EU) funded researchers are identifying and treating patients with Hepatitis B virus in West Africa with the aim of reducing their risk of dying from HBV and liver cancer through project PROLIFCIA. Read more.

China the Hardest Hit by Global Surge in Cancer, Says WHO Report
Feb 10 – China is bearing the brunt of new cancer cases and deaths amid an alarming global rise in the disease, with about 50% of new liver cancer cases recorded in China. Read more.

Hepatitis B and Kidney Transplantation
Feb 10 – Evaluating patients with hepatitis B serologies and HBV DNA viral load prior to kidney transplantation is essential to a successful kidney transplant for those with a current or prior hepatitis B infection. Read more.

CDC: Check Vaccines Before Attending Winter Olympics
Feb. 3 – Before attending the Winter Olympics in Sochi, Russia, U.S. health officials recommend travelers ensure their vaccinations are up to date, including hepatitis B. Read more.

Fish Spa May Spread HIV, Hepatitis B, Expert Warns
Feb. 3 – Fish spas are creating quite a splash in many areas, but health experts warn that the pedicures, where tiny fish nibble away the dead skin, may spread blood diseases such as HIV and hepatitis B. Read more.

British MPs Suggest Law to Ban Visas to Those Suffering From HIV and HBV
Feb 3 – Britain is mulling a draconian law that would ban foreigners with HIV and Hepatitis B from living or visiting the UK, which has caused uproar with civil society and activists urging rejection of the amendment. Read more.

B.C. Funds Hepatitis B Awareness Program for Asian Immigrants
Feb 3 – After years of lobbying, B.C.’s Ministry of Health is spending $400,000 on a hepatitis B education program aimed at Asian immigrants with Mandarin and Korean public information sessions scheduled first, to be followed with Punjabi, Tagalog and English. Read more.

NGMC Recognized for Protecting Newborns From Hepatitis B
Jan 27 – Northeast Georgia Medical Center (NGMC) has been recognized by the Immunization Action Coalition (IAC) and the Georgia Department of Public Health for achieving one of the highest reported rates in the state for its work to protect newborns from hepatitis B virus infection. Read more.

Children’s Patients May be at Risk of Infection After Colonoscopies
Jan 27 – More than 100 patients who had colonoscopies between 2011 and 2013 at Seattle Children’s have been advised to be tested for hepatitis B and C and HIV after the hospital discovered special equipment used in the procedures had not been properly cleaned. Read more.

Cooking Up Cancer?
Jan 27 – Grilling meats is an American tradition, but it’s not the healthiest thing to do. Research suggests that cooking meats over a flame is linked to liver and other cancers due to exposure to polycyclic aromatic hydrocarbons (PAHs). Read more.

Omega-3 Fatty Acids May Have Even More Health Benefits Than Thought
Jan 27 – Recent research shows that omega-3 fatty acids may offer protection against diet-induced nonalcoholic fatty liver disease (NAFLD), which can lead to nonalcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma and liver failure. Read more.

Monitoring Inactive Hepatitis B Patients is a Cost-Effective Strategy
Jan 21 – A novel study determined that monitoring inactive chronic hepatitis B carriers is a cost-effective strategy for China. However, results published in Hepatology show that increasing treatment, monitoring and adherence to therapy are necessary to achieve significant health benefits at the population level. Read more.

Patients of Dentist at North Sydney Clinics, Australia, Informed of Possible Exposure to HIV, Hepatitis
Jan 21 – Almost 1000 patients treated by a Sydney dentist over the past decade may have been exposed to HIV and hepatitis B and C because medical equipment was not properly sterilized. Patient advocates say the case raises ''deeply concerning'' questions about patient safety in dental clinics and the quality of medical regulation. Read more.

Cigarettes More Dangerous Than Ever
Jan 21 - Smoking cigarettes can cause even more health problems than previously known, including liver and colon cancer, blindness, diabetes, and erectile dysfunction, said a major US government report on Friday. Read more.

Cost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention Program
Jan 13 – The current CDC perinatal hepatitis B prevention program, is a cost-effective use of resources, but a program that reached all pregnant women would provide additional public health benefits, according to results of a recent analysis. Read more.

China Focus: Panic Leads to Drop in Hepatitis B Vaccination Rate
Jan 13 – Panic triggered by alleged vaccine-related deaths in China led to a 30 percent drop in the hepatitis B vaccination rate in December, with experts warning of rising incidence of HBV infection, despite conclusions by health authorities that the vaccine was not responsible for the deaths. Read more.

Nurse exposed 24 Buckeye inmates to hepatitis B and C
Jan 13 – For the second time in 17 months, inmates at the State Prison Complex-Lewis have been exposed to life-threatening disease by a health-care provider as a result of improper injection practices. Read more.

China Denies Hepatitis Vaccine Killed Nine Children
Jan 6 – Vaccines did not cause the deaths of nine children shortly after they were inoculated for hepatitis B as part of the Chinese government program, and no links have been found in eight other cases still being investigated by Chinese health authorities. Read more.

Hepatitis B and C Reduce Survival by More than 20 Years
Jan 6 – People with chronic hepatitis B or C lived about 2 decades less on average than those who did not have these infections, and chronic viral hepatitis was the 15th leading cause of death in the U.S. in 2010, CDC researchers reported in the January 1, 2014 Issue of Clinical Infectious Diseases. Read more.

Nigerian Federal Government Inaugurates Technical Group on Hepatitis Disease Control
Jan 6 – The Nigerian Federal Government has inaugurated a Technical Working Group on Viral Hepatitis Control in Nigeria, as a quick intervention on the increasing burden of viral hepatitis in a country where there is an 11% prevalence of HBV and 2.2% HCV prevalence. Read more.

Surgery Tied to Better Survival Outcomes in Huge Liver Tumors
Jan 6 – Surgical resection of huge hepatocellular carcinomas was linked with better survival outcomes versus transarterial chemoembolization (TACE), researchers found. Read more.


TOP 10 HBV STORIES IN 2013   December 30, 2013


Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B

Joint Agency Letter to Health–related Schools Regarding Hepatitis B Discrimination

Hepatitis B Treatment with Entecavir or Tenofovir Lowers But Does Not Eliminate HCC Risk

Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity

FDA Strengthens Hepatitis B Warning on 2 Cancer Drugs, Arzerra and Rituxan to Prevent HBV Reactivation

Hepatitis B Vaccination Cuts Deaths From Liver Disease, Cancer

Low Vitamin D Linked to Hepatitis B

Coffee Consumption Reduces Risk of Liver Cancer

Hepatitis B Vaccine Protection Lasts at Least 30 Years


Tenofovir May Help Mother-to-Child Hepatitis B Transmission

Diabetes Identified as Risk Factor for Liver Cancer Across Ethnic Groups
Dec 16 – Diabetes was associated with an increased risk for developing hepatocellular carcinoma, and this association was highest for Latinos, followed by Hawaiians, African-Americans, and Japanese-Americans. Read more.

Genetic Flaw in Males Triggers Onset of Liver Cancer, Diabetes
Dec 16 – Michigan State University researchers have uncovered a genetic deficiency in males that can trigger the development of one of the most common types of liver cancer and type 2 diabetes. Read more.

Universalization of Hepatitis B Vaccination Would be Taken Up with the Centre
Dec 16 – The Indian Society of Gastroenterology is appealing to the Union Health Ministry with the intent of universalizing the hepatitis B vaccine across all sections of the country. Read more.

About 2 Percent of Iranian Population Suffers from Hepatitis B
Dec 16 – About 1.4 million Iranians suffer from Hepatitis B, which indicates the average prevalence of the disease is about 2 percent. At the same time, the number of people infected with hepatitis B is declining. Read more.

Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years
Dec 9 – Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to maintain viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at AASLD 2013. Read more.

China's Struggle With Hepatitis B Discrimination
Dec 9 – Despite a 2010 law banning hepatitis B screening in job and school admission applications, HBV discrimination abounds in China, and seeking justice remains a challenge. Read more.

Peru: Liver Cancer Like No Other
Dec 9 – Liver cancer is the sixth most common cancer worldwide, most often affecting men over 40, and those with cirrhosis or hepatitis B or C. But in Peru, it also uncharacteristically affects young people who do not have the identified related risk factors. Read more.

Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the AASLD
Dec 2 – The FDA announced the requirement of a Boxed Warning for the anti-cancer immunosuppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab), and is specific to the risk of reactivating hepatitis B in patients who were previously infected with the virus. Read more.

Arrowhead Submits Phase 2a Application for Hep B RNAi Candidate
Dec 2 – After announcing promising new data, Arrowhead has submitted its application to begin a phase II-a trial of ARC-520. Researchers will look to determine the effect of one intravenous dose of ARC-520, in combination with the oral antiviral entecavir, on hepatitis B surface antigen reduction. Read more.

Vaccine Implant Could Eliminate Painful Booster Shots
Dec 2 – Scientists in Europe have devised a novel new system that might one day replace booster shots. Patients would swallow a pill to trigger the release of vaccine doses from a gel implant placed beneath the skin. Read more.

Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity
Nov 25 – A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 2013 AASLD Liver Meeting. Read more.

Hepatitis B and C Rates Higher Than Government Estimates
Nov 25 – A new federal government study provides the first estimates of the proportion of the population infected with the hepatitis B and C viruses, but experts say the figures significantly downplay the scale of the problem in Canada. Read more.

'Silent Epidemic' - Nearly Ten Percent of Filipinos Infected With Hepatitis
Nov 25 – Almost 10% of the Philippine population are infected with viral hepatitis, forcing experts to say that the situation is a "silent epidemic." 7.3 million are infected with chronic HBV and 1 million are infected with HCV. Read more.

B.C. Man Accused of Illegal Dentistry Turns Himself In
Nov 25 – A follow up on a British Columbia man, David Wu, accused of illegal dentistry, practicing out of his dirty, disorganized bedroom with unsterilized instruments. Most patients were young Chinese-Canadians now at risk for hepatitis B, C or HIV. Read more.

Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure
Nov 18 – A dual regimen of entecavir (baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to data presented at the 2013 AASLD Liver Meeting. Read more.

Hepatitis B Vaccine Protection Lasts at Least 30 Years
Nov 18 – Hepatitis B vaccination provides long-term protection through 30 years for a majority of recipients, and more than 90% were protected with either initial immunization or a booster, according to a presentation at the 2013 AASLD Liver Meeting. Read more.

Genovate and ScinoPharm Co-Develop Hepatitis B Drug "Livepro"
Nov 18 – Generic drug Livepro, (Entecavir) will be commercially available in Taiwan at the end of the year and is a joint development product of Genovate and ScinoPharm. Read more.

HBV Response to Tenofovir Similar in People With and Without HIV
Nov 18 – Nearly 90% of people with chronic hepatitis B virus in a Spanish group attained an undetectable HBV load after 96 weeks of tenofovir. Response rates did not differ between people with and without HIV infection. Read more.

Hepatitis B Treatment with Entecavir or Tenofovir Lowers But Does Not Eliminiate HCC Risk
Nov 11 – While entecavir or tenofovir can reduce the risk of hepatocellular carcinoma, people with chronic hepatitis B should continue to undergo regular monitoring for liver cancer. Better predictive models may also be needed for Caucasian patients. Read more.

Early Treatment With Nucleotide/Nucleoside Analogues Safe, Effective for HBV-Induced Liver Failure
Nov 11 – Immediate treatment of hepatitis B virus induced acute liver failure with nucleotide/nucleoside analogues is well tolerated and avoids liver transplantation, researchers reported at the 2013 AASLD Liver Meeting. Read more.

Viral Hepatitis is a Leading Cause of Death Worldwide
Nov 11 – Chronic viral hepatitis was identified as one of the leading causes of mortality worldwide, according to the 2010 Global Burden of Disease Study presented at the 2013 AASLD Liver Meeting. Read more.

The Prevalence of Fibromyalgia Among Patients with Hepatitis B Virus Infection
Nov 11 – Fibromyalgia, characterized by widespread and chronic musculoskeletal pain and fatigue, appears to be more prevalent among patients with hepatitis B, according to a recent study. Read more.

Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B
Nov 4 – Data presented at the AASLD Liver Meeting demonstrated a reduction of key HBV antigens and DNA and a therapeutic immunological flare, which could lead to HBsAg seroconversion and a functional cure for HBV. Read more.

Fast, Painless Alternative to Liver Biopsies for Hepatitis Patients Proves Accurate and Reliable
Nov 4 – FibroScan, a non–invasive alternative to liver biopsy, the current standard method of diagnosing cirrhosis in hepatitis patients, proves very reliable in a national multi–center. Read more.

Barber with Hepatitis B Jailed in Dubai for Offering Bribe Over Blood Test
Nov 4 – A barber with Hepatitis B and two coworkers who tried to bribe a municipality health worker into falsifying blood test results have been sentenced to one year in prison. Workers seeking work permits in the UAE are screened and deported if they are found HBV positive and intend to work with the public, including barbers and salon workers. Read more.

Researchers Recently Launched Collaborative Hepatitis Network in Africa
Nov 4 – Physicians and researchers from Africa, the United States and Europe recently launched the Africa Collaborative Hepatitis Network, known as HepNet to study how to better prevent and control viral hepatitis. Read more.

Asian Americans Comprise Half of All People with Hepatitis B in the U.S.
Oct 28 – Local hepatitis B advocates in Seattle debunk HBV myths and state we need more education to overcome stigma affecting Asian and Pacific Islanders (APIs). While APIs account for less than 5 percent of the U.S. population, they comprise half of the estimated 1.2 million people living in the United States with chronic hepatitis B. Read more.

Coffee Consumption Reduces Risk of Liver Cancer
Oct 28 – A meta-analysis of 16 studies consistently showed that a moderate amount of coffee consumption, particularly three cups a day, could possibly reduce the risk of liver cancer by 50 percent. Read more.

Scientists Find that Activating Family of Small Proteins Could Suppress Liver Malignancies
Oct 28 – Signaling crosstalk between different protein switches has an influence on the development of cancer and paves the way for the development and application of therapeutics targeted at liver cancer, according to research from the National University of Singapore. Read more.

Son Gives Dad a Liver and a New Life
Oct 28 – A son gives his father the gift of life by donating part of his liver to his father, diagnosed with liver cancer due to chronic hepatitis B diagnosed 30 years ago. Read more.

Hepatitis B Mutation Seen in Only Men, Increased Risk of Liver Cancer
Oct 21 – A team of researchers identified a mutation from the hepatitis B virus that seems to appear only in men and may explain why HBV-infected males are roughly five times more likely than HBV–infected women to develop certain types of liver cancer. Read more.

Entecavir and Tenofovir Both Work Well Against Hepatitis B in Clinical Practice
Oct 21 – Entecavir (Baraclude) and tenofovir (Viread) both demonstrated potent activity against hepatitis B virus in a Turkish study presented at the second IDWeek conference. Read more.

Hepatitis B Treatment in Real Life: Common & Uncommon Patient Profiles
Oct 21 – The Asian Health Foundation is hosting a CME/CE certified educational dinner meeting series in 6 cities across the U.S., and will provide Health Care Professionals with an understanding of treatment strategies for hepatitis B. Read more.

Arrowhead to Present at Upcoming Conferences Oct 21   Arrowhead Research Corporation will present data on ARC-520, its hepatitis B drug candidate, at two scientific conferences including the 2013 International Meeting on Molecular Biology of Hepatitis B Viruses in Shanghai, coordinated by the Hepatitis B Foundation, and the AASLD Liver Meeting in Washington, DC.Read more.

Vaccination Campaign Doubles HBV Mutations
Oct 14 – A universal infant vaccination campaign in China has led the Hepatitis B virus to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies. Read more.

Tenofovir May Help Mother-to-Child Hepatitis B Transmission
Oct 14 – Taking tenofovir during the final months of pregnancy may provide extra protection against perinatal transmission of hepatitis B virus, along with immunization of the infant, according to a presentation at the IDWeek conference. Read more.

Arrowhead Initiates Phase 1 Study of ARC-520 for Treatment Against Chronic HBV Infection
Oct 14 – Arrowhead announced that it completed enrollment in a phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B. Initial data indicate that ARC-520 is generally safe and well tolerated at all six dose levels studied. Read more.

Researchers Identify Liver Cancer Progenitor Cells Before Tumors Become Visible
Oct 14 – Researchers have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma (HCC) tumors, according to researchers at the University of California, San Diego School of Medicine. Read more.

Hepatitis B Foundation’s Research Institute Renamed for Nobel Prize Winner Dr. Baruch S. Blumberg
Oct. 7 - The Hepatitis B Foundation officially renamed its research institute the "Baruch S. Blumberg Institute" in a grand re-opening ceremony today to honor the scientific legacy of the Foundation’s co-founder, Dr. Baruch Blumberg who won the Nobel Prize for his discovery of the hepatitis B virus. Featured guest speaker was Mr. Mark Thompson, President and CEO of The New York Times, who is also the son-in-law of the late Dr. Blumberg. Read more.

Entecavir, Tenofovir Comparable in Patients with Treatment-Naïve Chronic Hepatitis B
Oct 7 – Third-year results of a “real-world” cohort study found the antivirals entecavir and tenofovir provided comparable efficacy for treatment–naïve patients with chronic hepatitis B and high genetic barriers against resistance, a study concluded at IDWeek 2013. Read more.

High HBV Viral Load Raises Risk of Progression to Liver Cancer
Oct 7 – Hepatitis B patients with high HBV DNA levels, indicating active viral replication, are more likely to experience progression of abnormal liver nodules to hepatocellular carcinoma, researchers reported at the 7th International Liver Cancer Association Annual Conference (ILCA 2013). Read more.

HBV Vaccine Response Status Not Associated with cART CD4 Gains at 1-Year
Oct 7 – Hepatitis B virus vaccine response status was not associated with post–combination antiretroviral therapy (cART) CD4 gains at 1-year among those with virologic suppression, a study concluded at IDWeek 2013. Read more.

Drug Use Blamed for Rise in Hepatitis B Cases
Oct 7 – At a recent Harrison-Clarksburg Health Department meeting in West Virginia, hepatitis B rates were a notable topic of discussion. Read more.

FDA Strengthens Hepatitis B Warning on 2 Cancer Drugs
Sept 30 – U.S. health regulators have strengthened the warnings on two blood cancer drugs to reflect the risk that they may reactivate the hepatitis B virus in patients previously infected with the disease. Read more.

Preventing Mother-to-Child Transmission of HBV
Sept 30 – Pregnant women with hepatitis B are less likely to pass the virus on to babies delivered by elective cesarean section, compared to those delivered naturally or by urgent cesarean section, according to researchers. Read more.

Published Phase 3 Data on HEPLISAV Shows Safety and Effectiveness
Sept 30 – Dynavax announced results of two Phase 3 trials of HEPLISAV published in J. Vaccine, which concluded that HEPLISAV induced significantly higher seroprotection rates in all groups (including hypo-responsive populations) than the approved HBV vaccine in a shorter 2-dose schedule over one month while maintaining a similar safety profile. Read more.

New Test Enables Early Diagnosis of Liver Cancer
Sept 23 – Researchers have found a way to make early liver cancer show its true colors. They have developed a test that will help pathologists clearly distinguish early liver cancer cells from nearly identical normal liver cells by giving them a distinctive red-brown hue. Read more.

Patient, Heal Thyself: Solution to Personalized treatment for Chronic Infections Could Lie in Patient's Own Blood
Sept 23 – There’s hope for a new personalized treatment strategy that could use a patient's own blood to treat chronic hepatitis B and C infections using vaccine therapies. Read more.

Army Recruits Dropped Over Hepatitis B, HIV/AIDS
Sept 23 - Hundreds of youth who turned up for the three-day Uganda People’s Defense Forces (UPDF) recruitment exercise in Kampala were disqualified after they tested positive for Hepatitis B or HIV/AIDS. Read more.

Age is No Deterrent in Dream to Save Lives
Sept 23 – 91-year-old Wu Mengchao is among China’s most renowned doctors in the field of liver cancer treatment and research. His drive and accomplishments are admirable. Read more.

114 Children Hospitalized After Being Given Hepatitis B Vaccine Instead of Pulse Polio Drops
Sept 16 – In a major medical goof up, as many as 114 children were hospitalized in West Bengal after they were mistakenly given Hepatitis B vaccine orally instead of Pulse Polio drops on Sunday. Read more

High Rate of New Hepatitis B Among African-Americans
Sept 16 – Black Americans have a higher incidence of hepatitis B virus infection (new infections) than any other racial/ethnic group according to a review article of Clinical Gastroenterology and Hepatology. Read more

HIV and Hepatitis Risk for Steroid Users
Sept 16 - People who inject anabolic steroids and tanning drugs are at a higher risk of HIV and viral hepatitis, a study from Public Health England (PHE) has revealed. Read more.

OSHA Fines Atlanta Health Careers Institute
Sept 16 – OSHA fined Atlanta Health Careers Institute LLC $62,000 for allegedly not training properly employees in a bloodborne pathogen program and not making available the Hepatitis B vaccine to workers exposed to potential bloodborne pathogen hazards. Read more.

Hep B Vaccination May Cut Deaths From Liver Disease
Sept 9 – Taiwanese researchers report a 90 percent reduction in deaths from complications of hepatitis B and a decrease in the spread of hepatitis B since the country began its infant vaccination program in 1984. Read more

Tenofovir is Highly Effective for HIV/HBV Co-infection, Meta-Analysis Shows
Sept 9 – Tenofovir, which has potent activity against both HIV and hepatitis B virus, is the most effective hepatitis B treatment for people with HIV and HBV co-infection, according to a 23-study meta-analysis. Read more

Cancer Experts Detail New Approaches to Liver Cancer Treatment with Stereotactic Ablative Radiotherapy
Sept 9 – Clinical experts outlined promising new approaches to treating liver cancer using radiosurgery with advanced imaging and motion management technology, since many patients are not eligible for a liver transplant or surgery. Read more.

Redistricting Might Shorten Wait for Liver Transplants
Sept 3 – Where you live can affect your chances of getting a liver transplant and your risk of dying while waiting. William Sherbert learned this lesson when liver failure from hepatitis B put him on the transplant list. Read more

Ramon Magsaysay Awards: Pinoy Doc Champions Health Care for All
Sept 3 - Filipino hepatologist and Ramon Magsaysay awardee, Dr. Enesto Domingo, discusses the challenges in addressing hepatitis B and liver cancer in the Philippines, and the need for universal HBV vaccination and health care for all. Read more

Western Australia (WA) Research Circumvents Stem Cell Cancer Risk
Sept 3 – The clinical use of multipotent stem cells to regenerate new tissue and organs may be perceived by some as the solution of the future, but is this evidence conclusive? Read more.

Smart Syringe Turns Red to Tell You It's Been Used
Sept 3 – An innovative solution to the global problem of unsterilized second-hand syringes may save thousands of lives each year by reducing the transmission of blood-borne diseases such as hepatitis B, hepatitis C, and HIV. Read more

Novel Biomarker Could Potentially Lead to Early Detection of Liver Fibrosis
August 26 – A study reveals the central role of the immune molecule interleukin 33 (IL-33) in the formation of liver fibrosis, suggesting its use as a biomarker to potentially lead to early detection of fibrosis in patients. Read more

German Surgeons Perform Liver Cancer Operation Using Tablet
August 26 – The first of its kind liver cancer operation was conducted with the help of a tablet and a new app, promising support for surgeons in reducing the rate of complications during operations. Read more.

Galectin Therapeutics Targets Silent Epidemic in Liver Fibrosis
August 26 – Galectin Therapeutics, focusing on diseases such as fatty liver disease where galectin proteins play a major role in the disease process, has developed 2 classes of galectin inhibitors. The company is currently enrolling NASH patients with advanced fibrosis in a dose escalated Phase 1 study. Read more

Call for Coalition Hep B Commitment
August 26 – Peak health bodies are calling on the Coalition to commit to funding what they say are urgently needed hepatitis B treatment and awareness programs. Read more

GAVI Alliance Bridges China-Africa Immunization Cooperation
August 19 – The GAVI Alliance held an event to share the Chinese experience of immunization with African health ministers at the China-Africa health forum, which focused on the lessons learned from China's hepatitis B vaccination program. Read more

When Vaccinations Fail to Cause Response: Causes Vary with Vaccine and Person
August 19 – Most people react very well to vaccinations and have an adequate immune response against the pathogens. However, reasons for a non-response may vary. Read why some are hepatitis B vaccine non-responders. Read more.

Increased Caffeine Intake May Reduce Fatty Liver in People With NAFLD
August 19 – Surprise! Your morning cup of tea or coffee may be doing more than just perking you up before work, suggests an international team of researchers led by Duke-NUS Graduate Medical School and the Duke University School of Medicine. Read more

Hepatitis C Outbreak: In Wake Of Kwiatkowski Guilty Plea, Patients Seek Accountability
August 19 – Patients at a New Hampshire hospital who were infected with hepatitis C by a traveling medical technician with a drug problem are pleased with his guilty plea but are still pushing to hold others accountable. Read more

New Gene Therapy Advance Holds Promise for the Treatment of the Global Killer HBV
August 12 – A new gene therapy approach based on the engineering of a new class of proteins called TALENs recognizes and may disable the DNA of HBV. Read more

End This Neglect of Viral Hepatitis
August 12 – With mortality rates comparable to HIV/Aids, TB and malaria, is it time the global health community addressed viral hepatitis with the urgency it needs? Read more.

Urgent Call to Avert Hepatitis B Crisis
August 12 – Migrant communities in Melbourne’s west are being urged to protect against hepatitis infection as experts warn that Australia faces a hepatitis B crisis. Read more

Learn From My Friend’s Death: Love Your Liver
August 12 – Reflecting on the tragic loss of a friend, this author and co-founder of the Al D. Rodriguez Liver Foundation raises viral hepatitis awareness. Screen. Vaccinate. Don't Hesitate. Read more

China Nixes Patent for Gilead HIV, Hepatitis Drug Viread
August 5 – China officials have revoked the patent protecting Gilead Sciences Inc.'s HIV and hepatitis B drug, Viread. What does this mean for those living with chronic hepatitis B? Read more

Hepatitis B Treatment with Entecavir Lowers Risk of Liver Cancer
August 5 – Long-term treatment with entecavir significantly reduces the chances of developing hepatocellular carcinoma compared with no treatment, and appears to lower the risk more than an older drug, especially for the most at-risk patients, according to a report in the July 2013 issue of Hepatology. Read more.

Boston Patients Exposed to Virus Due to Lack of EHR Training
August 5 – Thirteen dialysis patients at Boston Medical Center were exposed to hepatitis B earlier this year when two nurses from an outside dialysis contractor failed to receive access to the hospital’s EHR system, which would have let them know that an infected patient had used equipment that was then shared with the victims. Read more

'Two-Thirds of Injections in India Unsafe’
August 5 – Two-thirds of injections being used in India are unsafe, posing health hazards such as hepatitis B, hepatitis C, and HIV. According to WHO, up to 40% of injections worldwide are given with syringes and needles reused without sterilization. Read more

WHO Urges Governments to Act on Hepatitis Threat
July 29 - WHO is urging governments to act against the five hepatitis viruses that can cause severe liver infections and leads to 1.4 million deaths every year. WHO also released its first-ever country hepatitis survey, covering 126 countries. Read more

Group Wants Law for Workers With Hepa B – Philippines
July 29 – A group of doctors called on lawmakers to pass a bill that will set clear-cut policies to protect workers who test positive with hepatitis B in the workplace in the Philippines. Read more.

Israel's SciVac Eyes Global Expansion of 3G Hepatitis B Vaccine
July 29 - Israeli drug company SciVac is seeking U.S. approval for a widely used hepatitis B vaccine as part of a push for increased global sales of a product, which it says could stem global growth in the disease. Read more

Film Fights the Scourge of Hep B
July 29 – An Australian-Vietnamese soap-opera drama uses comedy and drama to tackle hepatitis B taboos, debuted at Hoyts Wetherill Park, Australia. Read more

In Asia Pacific, One Death Every 30 Seconds From Viral Hepatitis
July 22 – The number of people dying from viral hepatitis has reached one million every year in the Asia Pacific Region, a death rate that is three times higher than HIV/AIDS. Read more

Many People Need Hepatitis B Treatment in Gambia
July 22 - About 8% of people tested through a community-based screening program in Gambia have hepatitis B, and about 8% of these have advanced liver disease and meet European criteria for antiviral therapy based on findings from PROLIFICA - Prevention of Liver Fibrosis and Liver Cancer in Africa, the first program aimed at testing, assessing, and treating chronic hepatitis B in West Africa. Read more.

Inequalities in the Treatment of Hepatitis Require EU Intervention
July 22 – Differences in prevention, detection and access to treatment of viral Hepatitis in different European Union member states are alarming. Read more

Hundreds Call Hepatitis Helpline
July 22 – Hundreds of people have been calling The Hepatitis Foundation of New Zealand following the launch of their “Can You Say Yes” hepatitis B campaign aimed at encouraging those at risk to be tested for hepatitis B. Read more

Cancer Among Asian Americans
July 15 – Liver cancer is a leading cause of death for Asian Americans, but few know chronic HBV is a risk factor. A new campaign, “Know Hepatitis B”, launched by the CDC and Hep B United aims to improve awareness, advocate for testing, and improve care, treatment and health outcomes by educating AAPI communities. Read more

Family Promise: Get Tested for Hepatitis B
July 15 – One in 12 Asian Americans has hepatitis B, but 2 in 3 don’t know they have it. Protect your family and get tested for hepatitis B. View the new CDC PSA.

Govt Steps Up Efforts in Fight Against Spread of Hepatitis
July 15 - Concerned about the high prevalence of hepatitis B, the Health Ministry will carry out nationwide screening tests for pregnant women this year to prevent further spread of the HBV, beginning in Jakarta. Read more

GLOMEF Intensifies Public Education on Hepatitis B
July 15 – The Global Media Foundation (GLOMEF), a human rights and anti-corruption media advocacy organization in Ghana has intensified public education on HBV, especially among the rural folk with much focus on market women and farmers. Read more

Recall of Possibly Tainted Hepatitis B Vaccine
July 8 – Pharmaceutical giant Merck & Co. voluntarily recalled a single lot of its hepatitis B vaccine due to the possibility of cracked vials, which may compromise sterility. Read more

Ancient Origin of Hepatitis B Viruses Revealed by DNA Fossils in Bird Genomes
July 8 – The hepatitis B virus originally infected birds back when the dinosaurs still roamed the planet, according to a newly published study of genomic bird DNA, a finding that may help improve human health outcomes. Read more

Intestine Bugs Could Be Key To Obesity-Cancer Link
July 8 – Researchers in Japan report that obese mice carry an altered gut flora, which is linked to an increase in the production of DNA-damaging acid that causes liver inflammation and cancer. Read more

Scientists Create ‘Human Liver’ From Stem Cells
July 8 – Scientists in Japan said they had grown human liver tissue from stem cells in a first that holds promise for alleviating the critical shortage of donor organs. Read more

New USPSTF Hepatitis C Testing Recommendation Hailed by NVHR
July 1 - U.S. Preventive Services Task Force (USPSTF) has released updated hepatitis C screening recommendations to test all people born from 1945 to 1965. Individuals born between these years have the highest rates of chronic infection and represent 75% of the more than 4 million cases of HCV in the U.S. Read more

Experts Warn of a Liver Cancer Time Bomb
July 1 - Increased diagnosis and treatment of people with hepatitis B is vital to prevent a liver cancer time bomb, experts warn. A liver cancer prevention policy launched by the Cancer Council on Monday calls for increased testing of groups at risk of hepatitis B, and notes that less than half of Australians affected are aware they carry the disease. Read more

Adherence To and Initiation of HBV Therapy Prove Problematic In Real-World Settings
July 1 - Mindie H. Nguyen, MD, of Stanford University School of Medicine presented two studies at DDW that found medical non-adherence can be a larger issue than antiviral resistance, and that many factors beyond patient noncompliance can contribute to this problem and lead to virologic breakthrough. Read more

Hepatitis B Total Rises to 18 in Investigation of North Charleston Center
July 1 – A total of 18 people have tested positive for HBV since the state health department launched an investigation into a North Charleston medical clinic since May. All the people involved received at least one injection from Tri-County Spinal Care Center, the health department said, because “several lapses in infection control procedures” were identified at the facility. Read more

Anti-HBV Vaccine Fails Against Chronic Hepatitis B
June 24 – A therapeutic vaccine candidate, aimed at breaking immune tolerance to the hepatitis B virus, failed in a recent trial, but the researchers believe the problem is that the adjuvant itself was too potent. Read more

Does HBV Suppression Prevent Liver Disease Progression?
June 24 – Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week 2013 meeting. Read more

More Patients Test Positive for Hepatitis in North Charleston Clinic Investigation
June 24 - Twelve patients of Tri-County Spinal Care Center have tested positive for hepatitis B, and the S.C. Department of Health and Environmental Control cannot determine when those individuals were infected. On May 17, DHEC notified the clinic of three patients who tested positive for hepatitis B after receiving invasive injections. Read more

Hep B United Partners with CDC on First-Ever Multilingual Hepatitis B Testing Campaign for AAPIs
June 17 – Hep B United joins the Centers for Disease Control and Prevention (CDC) in announcing the first-ever multilingual campaign for Asian Americans and Pacific Islanders (AAPIs), to increase testing for hepatitis B among this population across the United States. Read more

Scientists ID Gene Linked to Aggressive Liver Cancer
June 17 – Researchers have found a gene they say can help identify patients facing aggressive liver cancer, and may prove key to their future treatment. Read more

Bananas as Hepatitis B Oral Vaccine?
June 17 – Cornell researchers are currently considering bananas as a potential oral vaccine against the HBV virus in developing countries. Read more

Supreme Court's Human Gene Ruling Draws Local Interest
June 17 – HBF’s Dr. Timothy block weighs in on the recent Supreme Court ruling that human genes cannot be patented, and the impact on future research. Read more

Joint Agency Letter to Health–related Schools Regarding Hepatitis B Discrimination
June 13 - A historic letter on behalf of the Department of Justice, the Department of Health and Human Services, and the Department of Education has been issued regarding the participation of students with hepatitis B in health-related schools and programs. This letter emphasizes the importance of the updated CDC Recommendations and is a reminder of the institution's nondiscrimination obligations under the Americans with Disabilities Act. Read more

Eradication of Hepatitis B: A Nationwide Community Coalition Approach to Improving Vaccination, Screening, and Linkage to Care
June 10 - Hep B United, a national campaign to support and leverage the success of community-based HBV coalitions provides a strategic response to the HHS Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. Read more

Low Vitamin D Linked to Hepatitis B
June 10 – Vitamin D deficiency might be a key player in hepatitis B replication, researchers reported. Read more

Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus
June 10 – The newer antivirals tenofovir and entecavir inhibit HBV replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting. Read more

160,000 Singaporeans Suffer From Hepatitis B, Chronic Hepatitis B
June 10 – Some 160,000 or 2.7% of Singapore’s population suffer from hepatitis B, where HBV is the most common cause of liver diseases and liver cancer as revealed at the Asian Pacific Association for the Study of Liver Week (APASL). Read more

Community Health Workers Help Increase Hepatitis B Screenings in the Asian American Population, Experts Say
June 3 – Great way to end Hepatitis Awareness Month with an update on community events that are getting more Asian Americans screened for hepatitis B. Read more

DHEC Digs Into 2 Years of Records in Hepatitis B Investigation
June 3 – The Department of Health and Environmental Control is now seeking to test as many as 500 people who visited a North Charleston spine clinic and received injections. Read more

Liver Cancer Rates a Wake-Up Call That It's Time to Address Liver Disease Epidemic
June 3 – New Canadian Cancer Statistics show that liver cancer is one of the fastest rising forms of cancer in Canada, and is a direct result of contributing liver diseases like hepatitis B and C and fatty liver disease not being identified and treated early enough. Read more

Cedar Rapids Man Gets Prison in False Hepatitis B Claim
June 3 – A Cedar Rapids man has been given prison time for posting false information on Facebook about a consumer product being tainted with Hepatitis B. Read more

AASLD Members at Forefront to Raise Awareness of Hepatitis B and C
May 28 – Viral hepatitis is an asymptomatic disease affecting more than 5.3 million Americans. The AASLD, NVHR, and other partners were pleased to participate with the Congressional Hepatitis Caucus to provide testing for hepatitis B and C and raise awareness at the US House of Representatives. Read more

Got a Fatty Liver? Here’s How to Beat the Flab
May 28 – Fatty liver, one of the causes of liver cancer, can be a scary diagnosis, but gastroenterologists say that with dietary changes and regular exercise, progression of liver damage can be prevented. Read more

Clinic 'Shocked' After 3 Patients Diagnosed With Hepatitis B
May 28 – A Charleston spinal care center is working with the S.C. Department of Health and Environmental Control after receiving the "shocking" news that 3 of its patients contracted hepatitis B after getting injections there. Read more

HHS Viral Hepatitis Action Plan Will Be Renewed
May 20 - The U.S. HHS National Viral Hepatitis Action Plan is celebrating its 2nd anniversary this year and Dr. Howard Koh, Assistant Secretary for Health of HSS, has announced that the partner agencies are committed and dedicated to renewing the Action Plan for another three years. The federal partners are currently working on their vision and priorities for 2014–2016. Read more

Hepatitis B Virus Linked with Non-Hodgkin’s Lymphoma
May 20 – Individuals with chronic hepatitis B virus infection may have an increased risk of developing non-Hodgkin’s lymphoma, according to findings recently published in The Lancet Oncology. Read more

NJ Recognizes May As National Hepatitis Awareness Month
May 20 – The New Jersey Department of Health, leader of an active HBV coalitions and Hep B United member, recognizes May as National Hepatitis Awareness Month. Read more

Bayer Begins Phase III Trial of Regorafenib in Patients with Hepatocellular Carcinoma
May 20 – Bayer HealthCare has started to enroll patients in an international phase III trial to evaluate the efficacy and safety of regorafenib for the treatment of patients with hepatocellular carcinoma who have progressed on sorafenib treatment. Read more

Eliminating Perinatal Transmission of Hepatitis B: More Than Just A Test
May 13 – Tackling and eliminating perinatal hepatitis B in the United States through the Viral Hepatitis Action Plan initiatives, vital partners and the implementation of provisions of the Affordable Care Act. Read more

Do Asian Patients Respond Better to Pegylated Interferon for Hepatitis B?
May 13 – Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at the EASL International Liver Congress last month. Read more

Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
May 13 – Jennerex's Pexa-Vec, an oncolytic immunotherapy designed to treat advanced HCC patients who have failed sorafenib, has received FDA orphan drug designation. Read more

Novel Tests Improve Diagnosis of Two Types of Liver Cancer
May 13 – New data from two clinical trials that were presented at the International Liver Congress 2013, demonstrated substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma using diagnostic urine tests. Read more

Health Providers With Hepatitis B Are No Threat to Patients, Covered By Disability Law
May 6 – New guidelines and the recent Department of Justice settlement are powerful tools to combat hepatitis B discrimination of medical professionals and students who are HBV carriers. Read more

May is Hepatitis Awareness Month
May 6 – May 1 marked the start of the month-long observance of Hepatitis Awareness Month. The observance is an important element of government-wide efforts to raise awareness about viral hepatitis and decrease health disparities by educating communities about the benefits of viral hepatitis prevention, testing, care, and treatment. Read more

Combo of 2 HIV Drugs Can Control Hepatitis B
May 6 – The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), which are typically combined as Truvada, can suppress the hepatitis B virus in three-quarters of those with “immune-tolerant” infection. Read more

Genetic Fossils Betray Hepatitis B's Ancient Roots
May 6 – A virus that causes liver diseases in people may have infected birds that shared the planet with dinosaurs. Read more

Five Reasons Asian Americans Should Get Tested for Hepatitis B
April 29 – More than 1 million Americans have a lifelong, or chronic, infection of hepatitis B. This includes one out of every 12 Asian Americans. If you or your parents were born in Asia or the Pacific Islands, the Centers for Disease Control and Prevention (CDC) recommends that you get tested for hepatitis B. Read more.

Health-Care Worker Visits Increase Hepatitis B Screening Rates for Hmong Americans
April 29 – Lay health workers increased screening rates for the hepatitis B virus and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found in the first study of its kind. Read more.

Novel Therapeutic Approaches to Cure Chronic HBV Infection
April 29 – Exciting new data presented at the International Liver Congress 2013 include results from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus infection. Read more.

New Drug Stimulates Immune System to Kill Infected Cells in Animal Model of Hepatitis B Infection
April 29 – A novel drug, GS–9620, developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells. Read more.

Dozens of Oklahoma Dentist’s Patients Positive for Hepatitis
April 22 - Dozens of patients of an Oklahoma dental clinic shuttered for unsanitary conditions have tested positive for hepatitis, according to a joint statement issued by Oklahoma State Department of Health and the Tulsa Health Department. Read more.

FDA Approves FibroScan® for Non-invasive Liver Diagnosis
April 22 - Echosens™ announces its FibroScan® device received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on April 5th, 2013 and is now ready to market its pioneering technology in the United States. Read more.

Liver Disease a Major Cause of Illness and Death Across the European Union: Action Needed to Save Lives
April 22 – Liver disease is the cause of a considerable burden of illness across the European Union (EU), investigators report in The Journal of Hepatology as a result of viral hepatitis, consumption of alcohol and fatty liver disease. Read more.

Interferon Induces Persistent Viral Infection, Suggests A New Approach To Clearing Infections From AIDS To Hepatitis
April 22 – Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C. Read more.

Public Health Response to Improper Infection Control at Tulsa Dentist Office
April 15 – As of April 11, there were 2,432 people who visited the Tulsa Health Department clinic to be screened for hepatitis B, hepatitis C and HIV following the recent announcement regarding the public health response to the improper infection control practices of Tulsa oral surgeon W. Scott Harrington. Read more.

Scientists Test Smallpox Vaccine as Cancer Killer
April 15 - Scientists at the University of California San Diego are conducting a multicenter clinical trial to see if genetically engineered smallpox virus can be used to fight liver cancer. Read more.

Australian Medical Association Calls for Mandatory Proof of Vaccination
April 15 – Parents who fail to vaccinate their children should face barriers to enrolling them in school and childcare centers, the Australian Medical Association says. Read more.

Tenofovir and 3TC Prevent New Hepatitis B Infections in Gay Men Living With HIV
April 8 – The inclusion of 3TC or tenofovir in antiretroviral treatment regimens reduces the risk of infection with hepatitis B virus (HBV) for gay men living with HIV who have not been vaccinated against HBV. Read more.

Liver Diseases Pose Major Problem in Future for Health Care Professionals: Report
April 8 – British Columbia (B.C.) needs more resources dedicated to the awareness, prevention and treatment of liver disease if it is to head off a brewing public health crisis, says one of the province’s leading liver specialists. B.C. has the third-highest rate of chronic hepatitis B infection in Canada. Read more.

He Battled Liver Cancer Thrice, and Won
April 8 – An amazing 52 year-old man is the recipient of a liver transplant, and has battled liver cancer three times in ten years as a result of a hepatitis B infection passed to him at birth from his mother. Read more.

Oklahoma Dental Patients May Have Been Exposed to HIV, Hepatitis B, Hepatitis C
April 1 – Health officials are urging 7,000 patients of an Oklahoma dentist to be tested for potential exposure to HIV, hepatitis B and hepatitis C. Read more.

New NIH Award Aims to Reduce Asian American Hepatitis B Disparities Through Health Information Technology
April 1 – A new grant award by the National Institute on Minority Health and Health Disparities of the NIH will support the development of new Health Information Technology (HIT) strategies by AAPCHO to increase screening for chronic hepatitis B and reduce the impact of hepatitis B among high-risk Asian American and Pacific Islander (AAPI) populations. Read more.

Drug 'May Reverse Liver Disease'
April 1 – A cheap and readily available drug could reverse severe liver disease, even in patients who find it impossible to give up alcohol, research suggests, and may provide an alternative to a liver transplant. Read more.

Chinese Airline Sued for Hepatitis B Discrimination During Recruitment
April 1 – In what is believed to be the first court case involving hepatitis B discrimination in China’s airline industry, charter flight operator, Capitol Airlines is being sued for refusing to employ a pilot because he had HBV. Read more.

Responding to Viral Hepatitis Through Health Reform
March 25 – NASTAD releases the primer on viral hepatitis and the Affordable Care Act (ACA) in light of the ACA’s anniversary. The ACA provides an opportunity to not only improve access to essential care and treatment for people living with viral hepatitis, but to diagnose viral hepatitis earlier and prevent new infections. Read more.

Hep B Poorly Managed in Kids, Pregnant Women
March 25 – Mother-to-child hepatitis B transmission continues despite vaccination and immunoglobulin administration and there is “scope for considerable improvement”, say Victorian experts. Read more.

Hepatitis B Treatment Named as Top-Selling Drug for Last Year
March 25 – A pharmaceutical for the treatment of chronic hepatitis B was the top-selling drug in Taiwan last year, taking the top by replacing a drug tackling high blood pressure. Read more.

Soybean Meal Peptides Could Stop Colon, Liver and Lung Cancer Growth
March 25 – The bean used to make tofu could also have powerful anti-cancer properties, according to a new study published in the Journal Food Research International. Read more.

Listen to Hepatitis B and Liver Cancer by Dr. Robert G. Gish
Download March 6th Webinar

School Cheers as Student Donates Liver to His Dad
March 18 – A Taipei high school student puts his education on hold so he can donate part of his liver to his father, a hepatitis B carrier with cirrhosis. Read more.

Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B
March 18 – Arrowhead Research Corporation, a targeted therapeutics company, announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus supports findings from rodent models indicating that it can knock down HBV DNA and key viral antigens. Read more.

PEG-IFN May Improve Response to Entecavir for HBV
March 11 – Adding pegylated interferon alfa-2a to entecavir increases treatment response in patients with chronic hepatitis B virus infection who are HBeAg positive, according to preliminary results from an international clinical trial. Read more.

Pennsylvania Biotech Center, Created by Hepatitis B Foundation Has Huge Economic Impact
March 8, 2013 - The PA Biotechnology Center, created by the Hepatitis B Foundation, has generated $579 million for the region and state, and 573 jobs over the past 4 years, according to the Economic Impact Study 2013, released by Byler Associates. View Video.

Justice Department Settles with the University of Medicine and Dentistry of New Jersey Over Discrimination Against People with Hepatitis B
March 5 – The U.S. Justice Department has reached a settlement with the University of Medicine and Dentistry of New Jersey that resolves complaints that some applicants were unlawfully excluded because they have hepatitis B. Under the settlement, UMDNJ will adopt a disability rights policy and allow the applicants to enroll. The Hepatitis B Foundation is proud to have played a role in successfully advocating for these students. Read more.

Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus
March 4 – Drug developer Arrowhead Research Corp. released data demonstrating its RNAi-based candidate ARC-520 has the potential to treat chronic hepatitis B in a fundamentally different manner, with the goal of finding a functional cure. Read more.

Exposure to Hepatitis B Virus Activates Immunity in Young People, Suggesting Benefits for Earlier Treatment
March 4 – New research indicates therapeutic interventions currently withheld from younger patients with so-called ‘immune tolerance’ to hepatitis B, may in fact benefit from earlier treatment. Read more.

Tenofovir Plus Emtricitabine or Lamivudine Does Not Always Suppress Hepatitis B in HIV/HBV Coinfected
March 4 – HIV/HBV coinfected people with high hepatitis B virus levels and those who are HBeAg positive are at greater risk of not achieving HBV suppression after a year on tenofovir plus emtricitabine or lamivudine, but most did so eventually, as reported in AIDS. Read more.

Antioxidant N-acetlycystein Improves Survival of Transplanted Liver
March 4 – N-acetylcysteine (NAC) administered during recovery of a liver from a deceased donor can help reduce damage during transplantation and increase survival of the liver graft in the recipient, according to a study published in Liver Transplantation. Read more.

Considerable Proportion of HBV/HCV Cases Go Unreported
Feb 25 – Reporting of chronic hepatitis B virus and hepatitis C virus infections is improving, but is still incomplete, according to research published in the Feb. 15 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report. Read more.

Dynavax Slides as FDA Rejects Adult Hepatitis B Vaccine
Feb 25 – U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B vaccine and sought additional data to evaluate its safety, delaying the market entry of a faster-acting and less frequently needed vaccine for the liver-attacking infection. Read more.

Combining Tenofovir With FTC or 3TC Boosts Chances of HBV Suppression for People Co-Infected with HIV
Feb 25 – A study involving people co-infected with HIV and hepatitis B virus shows that antiretroviral therapy that combines tenofovir with FTC or 3TC has the best chance of suppressing HBV replication to undetectable level. Read more.

Publication of First Comprehensive Literature Review on the Burden of Liver Disease in Europe
Feb 25 – The European Association for the Study of the Liver (EASL) has unveiled its new publication “The burden of liver disease in Europe” a review of available epidemiological data, which suggests the leading causes of cirrhosis and primary liver cancer. Read more.

Chronic hepatitis B: What Should Be the Goal for New Therapies?
Feb 17 – Chronic hepatitis B can be medically managed with current therapies, but not reliably “cured”. Should the goals for new therapies and potential cures be redefined? Dr. Timothy Block, HBF President and Drexel University Professor, and co-authors offer clarification in Antiviral Research. Read more.

Chronic Viral Hepatitis in Cancer Patients Requires Personalized Management
Feb 17 – The likelihood of HBV reactivation during cancer treatment has led some oncologists to advocate for more thorough and standardized HBV screening guidelines. What decisions are being made regarding a patient’s need for antiviral therapy and the duration of such therapy? Read more.

Sounding the Alarm on a Silent Epidemic: Federal HIV/STD Advisory Group Adopts Viral Hepatitis as Priority
Feb 18 – In support of enhanced cross-government efforts to address the prevention, care and treatment of viral hepatitis, a federal advisory body on HIV and STDs recently expanded its scope and title to include viral hepatitis. Read more.

U.S. Court Invalidates Patent on Bristol Hepatitis B Drug
Feb 18 – A U.S. federal court has invalidated the U.S. patent on Bristol-Myers Squibb Company’s Baraclude treatment for hepatitis B after a challenge from generic drug maker Teva Pharmaceutical Industries. Read more.

Saint Louis University Research Aims Knockout Punch at Hepatitis B
Feb 11 – Saint Louis University investigators together with collaborators from the University of Missouri and the University of Pittsburgh report a breakthrough in the pursuit of new hepatitis B drugs that could help cure the virus. Researchers were able to measure and then block a previously unstudied enzyme to stop the virus from replicating. Read more.

Modified Smallpox Vaccine Stymies Liver Cancer in Study
Feb 11 – A genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival more than a year, a study found. Read more.

HIV Associated With Nonresponse to HBV Vaccine
Feb 11 – The response of adults with HIV to hepatitis B virus vaccination was investigated by researchers from the University of Washington and Kenyatta National Hospital in Kenya, and may provide best practices for re-vaccination of those with HIV infection that do not respond to the HBV vaccine. Read more.

One-Third Cases of Hepatitis B, C Preventable
Feb 11 – A recent study shows about one-third of the hepatitis B and C cases in Pakistan can be prevented by interventions directed towards a few selected and modifiable risk factors. Read more.

Chronic Hepatitis Cohort Study Sheds Light on Burden of Hepatitis B and C in U.S.
Feb 4 – People born between 1945 and 1964 account for the highest proportion of hepatitis B and C cases, and these viruses are a significant cause of illness and death, according to an analysis described in Clinical Infectious Diseases. Read more.

Medgenics Launches First Clinical Trial in Hepatitis to Use INFRADURE Tissue Treatment
Feb 4 – The first phase I/II study of INFRADURE, a subcutaneous autologous skin tissue implant for continuous production and delivery of interferon to treat HBV, HCV and HDV is underway, with the aim to replace months of weekly injections of interferon and associated serious side effects. Read more.

Celsion's Experimental Liver Cancer Treatment Fails in Late-Stage Trial
Feb 4 – Celsion Corporation announced its experimental liver cancer treatment, Thermo-Dox in combination with radio frequency ablation, failed to demonstrate significant progression free survival for patients with hepatocelluar carcinoma. Read more.

Government Commissions Research on Hepatitis B In Rwanda
Feb 4 – Rwanda’s Ministry of Health is conducting research to establish the prevalence of hepatitis B in the country. Read more.

NIH Awards AAPCHO Over $700,000 to Study Impact of Health Information Technology on Asian Americans Living With Viral Hepatitis
Jan 28 – The Association of Asian Pacific Community Health Organizations (AAPCHO) received a 3-year grant totaling over $700,000 from the NIH to develop new Health Information Technology strategies that increase screening for chronic hepatitis B and reduce the impact of HBV among high-risk Asian American and Pacific Islander populations. Read more.

Hepatitis B Genotype C Linked to Increased Hepatoma Risk
Jan 28 – Of all the major hepatitis B virus genotypes, genotype C carries the highest risk for hepatocellular carcinoma, Chinese researchers say. Read more.

Heavy Alcohol Use Increases Liver Cancer Risk for People With Hepatitis B
Jan 28 – Hepatitis B patients with liver cirrhosis who consumed large amounts of alcohol were more likely to develop hepatocellular carcinoma (HCC) than people who drank less, according to a report in the December edition of Hepatology. Read more.

Co-Infection With Hepatitis B or C is a Risk Factor for Reduced Bone Mineral Density Among Women With HIV
Jan 28 – After comparing bone mineral density between people with HIV infection alone and people with chronic viral hepatitis co-infection, a study published in the Journal of Acquired Immune Deficiency Syndromes found woman coinfected with hepatitis B or C and HIV had reduced bone mineral density. Read more.

Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B
Jan 21 – Advanced liver disease caused by hepatitis B virus, – including hepatocellular carcinoma and decompensated cirrhosis – accounted for more than 40% of deaths of people with chronic HBV in a large health maintenance organization, researchers reported in Hepatology. Read more.

Health Care-Related Exposure Linked to HCV, HBV Infection in Older Adults
Jan 21 – Older patients who received healthcare had increased risk of becoming infected with hepatitis B or hepatitis C. Patients' behavioral risks — being in jail, using "non-injected illicit drugs," or having sex with hepatitis-infected partners or with multiple partners — had no relation to this increased risk. Read more.

Mercer Counters High Hep B Numbers With Free Vaccinations
Jan 21 – West Virginia has the highest rate of Hepatitis B in the U.S., with Mercer County rates higher than both the state and national rates. Read more.

Viruses Prompt Oncogenic Transformation By Genetically Altering Infected Cells As Seen In Hepatitis B
Jan 21 – MiR–148a is repressed by hepatitis B virus X protein (HBx) to promote the growth and metastasis of liver cancer, as reported in the Journal of Clinical Investigation. Read more.

NIH Scientists Shed Light on Mystery Surrounding Hepatitis B Virus
Jan 14 – Scientists from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, and the University of Oxford, U.K., have shed light on a long-standing enigma about the structure of a protein related to the Hepatitis B virus were reported in Structure, and may lead to new therapeutic strategies for chronic liver disease. Read more.

Adolescents May Lose Hepatitis B Virus Protection Despite Vaccination as Infants
Jan 14 – New research presented in Hepatology reveals that a significant number of adolescents lose their protection from hepatitis B virus infection despite having received a complete vaccination series as infants. Read more.

716 Patients at VA May Have Been Exposed to HIV, Hepatitis
Jan 14 – More than 700 patients at the Buffalo VA Medical Center may have been exposed to HIV, hepatitis B or hepatitis C because of the inadvertent reuse of insulin pens intended to be used only once. Read more.

Hepatitis B treatment and Care in the UK Need to Evolve to Keep Pace With the Global Epidemic
Jan 14 – “Persistent HBV infection has changed its face in the UK,” research published in the online edition of Clinical Infectious Diseases shows. The study found considerable diversity in viral genotype and patient ethnicity, and that only one in three patients were taking therapy. Read more.

Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
Jan 7 – Treatment with tenofovir remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in The Lancet. Read more.

Treatment of HBeAg Positive Chronic Hepatitis B: Interferon or Nucleoside Analogues
Jan 7 – A review of clinical aspects of the management of chronic HBV with either interferon or nucleoside analogues are featured in Liver International, proceedings of 6th Paris Hepatitis Conference, International Conference on the Management of Patients with Viral Hepatitis. Read more.

Hepatitis B Vaccine 95% Effective in Reducing Cancer, Other Ailments
Jan 7 – A medical practitioner based in Abuja, Abiodun Ajayi, has called on Nigerians to adhere to WHO’s recommendation of Hepatitis B vaccination to prevent acute and chronic HBV and liver cancer cases. Read more.



Archived News Stories

*Please Note: Links to archived articles may have expired. If you are unable to access the page via the links below, try searching the HBV Research List Archives at

Archives: 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005


Connect with Us

facebook twitter youtube linkedin
Hep B Blog
Bookmark and Share
Site design by Ferguson Lynch  FL logo